Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Multiple Myeloma 44Recurrence 9Sarcoma, Kaposi 2Neoplasms, Plasma Cell 2Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Burkitt Lymphoma 2Acquired Immunodeficiency Syndrome 2Plasmacytoma 1Plasmablastic Lymphoma 1Multi-centric Castleman's Disease 1Malignant Plasma Cell Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Epstein-Barr Virus Infections 1

Interventions

Cyclophosphamide 23fludarabine 14Rituximab 14Specimen Handling 8Magnetic Resonance Spectroscopy 7Doxorubicin 7pirtobrutinib 6Vincristine 6Prednisone 6zanubrutinib 4polatuzumab vedotin 4obinutuzumab 4Nivolumab 4Etoposide 4Dexamethasone 4Biopsy 4tazemetostat 3tafasitamab 3pembrolizumab 3ibrutinib 3glofitamab 3fludarabine phosphate 3acalabrutinib 3Immunotherapy, Adoptive 3Bendamustine Hydrochloride 3venetoclax 2pomalidomide 2etoposide phosphate 2cemiplimab 2Prednisolone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × pomalidomide × 90 days × Clear all
NCT05389423 2026-06-01

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
25 enrolled
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT07532525 2026-04-16

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

University of Michigan Rogel Cancer Center

Phase 1 Not yet recruiting
12 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡